Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Dermata Therapeutics ( (DRMA) ) has shared an announcement.
On May 14, 2025, Dermata Therapeutics, Inc. announced that it had regained compliance with the Nasdaq’s minimum stockholders’ equity requirement, closing a previous issue reported on March 25, 2025. However, the company also received a notice on the same day indicating non-compliance with the $1.00 minimum bid price requirement, risking delisting from the Nasdaq Capital Market. Dermata plans to request a hearing to address this issue, but there is no assurance that their compliance plan will be accepted or successful.
The most recent analyst rating on (DRMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Underperform.
Dermata Therapeutics’ stock is primarily impacted by its financial health, characterized by significant operating losses and reliance on external financing. Technical analysis indicates a bearish trend with potential overselling, while valuation remains difficult to assess due to negative earnings. These factors contribute to a low overall score.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Average Trading Volume: 1,494,769
Technical Sentiment Signal: Sell
Current Market Cap: $4.7M
Find detailed analytics on DRMA stock on TipRanks’ Stock Analysis page.